Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
97.11
+0.34 (0.35%)
Dec 20, 2024, 4:00 PM EST - Market closed
Novartis AG Revenue
Novartis AG had revenue of $13.17B in the quarter ending September 30, 2024, with 8.93% growth. This brings the company's revenue in the last twelve months to $49.94B, up 8.92% year-over-year. In the year 2023, Novartis AG had annual revenue of $46.66B with 7.36% growth.
Revenue (ttm)
$49.94B
Revenue Growth
+8.92%
P/S Ratio
n/a
Revenue / Employee
$656,613
Employees
76,057
Market Cap
193.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 63.17B |
| Pfizer | 59.38B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Thermo Fisher | 42.37B |
| Abbott Laboratories | 41.22B |
| Amgen | 32.53B |
| Danaher | 23.74B |
NVS News
- 2 days ago - Some 330 jobs hit as Novartis closes Morphosys, WiWo reports - Reuters
- 8 days ago - Novartis: Time To Increase - Seeking Alpha
- 11 days ago - Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer - GlobeNewsWire
- 13 days ago - Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML - GlobeNewsWire
- 14 days ago - 12 High-Yield Dividend Aristocrats To Weather The Coming 2025 Storm In Style - Seeking Alpha
- 15 days ago - New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy - GlobeNewsWire
- 17 days ago - Novartis cannot block generic of best-selling heart drug, US appeals court says - Reuters
- 19 days ago - Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward - Seeking Alpha